Standard BioTools Inc (NAS:LAB)
$ 2.4 -0.01 (-0.41%) Market Cap: 909.27 Mil Enterprise Value: 892.58 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 70/100

Standard BioTools Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript

Aug 16, 2023 / 02:00PM GMT
Release Date Price: $2.85 (-0.70%)
Unidentified Participant

Well, good morning, everyone. Thanks for starting off day 2 here at the UBS conference. We'll start off this morning with an emerging life science technologies panels, focusing across Genomics and Proteomics. I have two CEOs from the emerging companies. We have Wenbin Jiang, who's CEO of Cytek Biosciences; and then Michael Egholm, who is President and CEO of Standard Biosciences.

Welcome, gentlemen. Thank you for joining us this morning.

Questions & Answers

Unidentified Participant

Maybe to start it off, could you two give us just a briefer overview of your companies, what kind of instruments you have? And how are you positioned in the market?

Michael Egholm
Standard BioTools Inc. - President, CEO & Director

Do you want to go first?

Wenbin Jiang

Yes. Cytek Biosciences is a company that providing cell analysis solution and the products that we have -- we actually provide a broad portfolio of flow cytometers including our full spectral flow

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot